{"gene":"CLSPN","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2000,"finding":"Claspin (identified in Xenopus egg extracts) is a novel protein that binds to Chk1; this binding is elevated in the presence of checkpoint-activating DNA templates. Immunodepletion of Claspin abolishes both phosphorylation and activation of Chk1 and prevents cell-cycle arrest in response to DNA replication blocks, establishing Claspin as an essential upstream regulator of Chk1.","method":"Protein identification, co-immunoprecipitation, immunodepletion from Xenopus egg extracts, kinase activity assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution in egg extracts with immunodepletion and direct kinase activation assay; foundational paper replicated by multiple subsequent studies","pmids":["11090622"],"is_preprint":false},{"year":2003,"finding":"Human Claspin is a cell-cycle regulated protein peaking at S/G2 phase that localizes to the nucleus and associates with Chk1 only following replication stress or DNA damage. Claspin is phosphorylated in response to replication stress, and this phosphorylation is required for its association with Chk1. Claspin also interacts with ATR and Rad9 (of the 9-1-1 complex), suggesting it acts as an adaptor bringing these checkpoint components together. siRNA-mediated knockdown of Claspin inhibits Chk1 activation and impairs the replication checkpoint.","method":"Co-immunoprecipitation, siRNA knockdown, cell-cycle analysis, premature chromatin condensation assay, DNA synthesis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Co-IP, siRNA, checkpoint readouts) in human cells; independently consistent with Xenopus findings","pmids":["12766152"],"is_preprint":false},{"year":2004,"finding":"Human Claspin is required for resistance to multiple genotoxic stresses (UV, IR, hydroxyurea). ATR-dependent phosphorylation of Claspin induces formation of a Claspin-BRCA1 complex. Claspin controls BRCA1 phosphorylation on serine 1524, suggesting a model where ATR phosphorylates Claspin, which recruits BRCA1 to jointly activate Chk1. Additionally, Claspin overexpression promotes cell proliferation, indicating a dual role as both a checkpoint mediator and a positive cell-cycle regulator.","method":"Co-immunoprecipitation, siRNA knockdown, phosphorylation mapping, cell proliferation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, reciprocal Co-IP, and defined phosphorylation site with functional readouts","pmids":["15096610"],"is_preprint":false},{"year":2006,"finding":"Claspin operates downstream of TopBP1 in the ATR signaling pathway and selectively mediates ATR-dependent phosphorylation of Chk1, but not other ATR substrates (Nbs1, Smc1, H2AX). Unlike TopBP1, Claspin remains distributed throughout the nucleus after DNA damage. TopBP1 is required for the DNA damage-induced interaction between Claspin and Chk1. Claspin depletion mimics Chk1 inactivation by inducing spontaneous DNA damage.","method":"RNAi knockdown, immunofluorescence, co-immunoprecipitation, western blotting for ATR substrate phosphorylation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — epistasis defined by orthogonal RNAi experiments; substrate specificity established by systematic phosphorylation analysis","pmids":["16880517"],"is_preprint":false},{"year":2006,"finding":"During recovery from the DNA replication checkpoint, Claspin is degraded via the SCF-βTrCP ubiquitin ligase. Plk1 phosphorylates a canonical DSGxxS degron in Claspin, enabling βTrCP binding and ubiquitylation. A stable Claspin mutant unable to bind βTrCP prolongs Chk1 activation and delays mitotic entry. In G2 DNA damage responses, Claspin proteolysis is inhibited to allow checkpoint maintenance.","method":"In vitro ubiquitylation assay, degron mutagenesis, co-immunoprecipitation, stable mutant expression, flow cytometry","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro ubiquitylation reconstitution with mutagenesis of degron, corroborated by functional cell-cycle assays; replicated in parallel by two independent labs","pmids":["16885022"],"is_preprint":false},{"year":2006,"finding":"Claspin is degraded at the onset of mitosis via its interaction with SCF-βTrCP; this interaction is phosphorylation-dependent, requires Plk1 activity, and depends on an intact phosphodegron in the N-terminus of Claspin. Stabilized Claspin (phosphodegron mutant or βTrCP knockdown) impairs Chk1 dephosphorylation and delays G2/M transition during recovery from checkpoint arrest. Thus, Plk1-driven Claspin degradation is essential for timely checkpoint recovery.","method":"Ubiquitylation assay, phosphodegron mutagenesis, siRNA, co-immunoprecipitation, live-cell imaging, flow cytometry","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods; independent replication alongside Peschiaroli et al. 2006 in the same journal issue","pmids":["16885021"],"is_preprint":false},{"year":2006,"finding":"Plk1-dependent proteasomal degradation of Claspin at mitotic entry controls termination of the Chk1-mediated checkpoint. Claspin interacts directly with both βTrCP and Plk1; inactivation of either or mutation of the βTrCP recognition motif in Claspin prevents mitotic degradation. A non-degradable Claspin mutant inhibits recovery from DNA-damage checkpoint arrest. Chk1 activity stabilizes Claspin during checkpoint response.","method":"Co-immunoprecipitation, proteasome inhibition, dominant-negative and RNAi approaches, flow cytometry, mitotic progression assay","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 2 — direct Plk1-Claspin and βTrCP-Claspin interaction shown with mutagenesis; functional checkpoint-recovery readout; consistent with two concurrent papers","pmids":["16934469"],"is_preprint":false},{"year":2006,"finding":"The deubiquitylating enzyme USP28 is required to stabilize Claspin (and other checkpoint mediators including Mdc1 and TopBP1) in response to DNA damage, counteracting ubiquitin-mediated degradation and sustaining checkpoint signaling.","method":"Co-immunoprecipitation via 53BP1 complex purification, siRNA knockdown, western blotting for Claspin stability","journal":"Cell","confidence":"Medium","confidence_rationale":"Tier 3 — Claspin stabilization by USP28 demonstrated by knockdown and protein level measurement; single lab, but consistent mechanistic logic","pmids":["16901786"],"is_preprint":false},{"year":2006,"finding":"Tim (Timeless) and its interacting partner Tipin facilitate the accumulation of Claspin in the nucleus under replication stress conditions. Knockdown of Tipin or Tim causes mislocalization of Claspin to the cytoplasm and impairs Chk1 phosphorylation under replication stress, demonstrating that the Tim-Tipin complex regulates Claspin nuclear localization and is required for full checkpoint signaling.","method":"siRNA knockdown, subcellular fractionation, immunofluorescence, Chk1 phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment with functional consequence (Chk1 activation); single lab","pmids":["17102137"],"is_preprint":false},{"year":2008,"finding":"In response to genotoxic stress in G2, APC/C(Cdh1) activation (triggered by Cdc14B-mediated Plk1 degradation) stabilizes Claspin by reducing Plk1-dependent phosphorylation required for βTrCP-mediated degradation. Claspin is also identified as an APC/C(Cdh1) substrate in G1. The deubiquitylating enzyme Usp28 counteracts APC/C(Cdh1)-mediated Claspin ubiquitylation to permit Claspin-mediated Chk1 activation in G2 damage response.","method":"In vivo ubiquitylation assay, co-immunoprecipitation, siRNA, substrate degradation assay, cell-cycle synchronization","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal mechanistic methods (ubiquitylation, Co-IP, degradation assays, epistasis); defines a novel APC/C(Cdh1) regulatory circuit for Claspin","pmids":["18662541"],"is_preprint":false},{"year":2020,"finding":"The CLSPN variant c.1574A>G (p.Asn525Ser) causes partial exon skipping and decreased Claspin expression, and reduces Chk1 activation in signaling experiments. This variant is significantly associated with breast cancer. A promoter variant c.-68C>T increases CLSPN transcriptional activity in a luciferase assay. These results demonstrate that CLSPN variants can modulate Claspin function by altering transcription, RNA processing, and Chk1 activation.","method":"Minigene splicing assay, luciferase reporter assay, western blotting for Chk1 activation, association study","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — functional splicing and signaling assays with defined variants; single lab","pmids":["32847043"],"is_preprint":false},{"year":2019,"finding":"Claspin (and Timeless) are overexpressed in cancer cells and function to protect replication forks from oncogene-induced replication stress in a checkpoint-independent manner. Reducing Claspin and Timeless to pretumoral levels impedes fork progression without affecting ATR-Chk1 checkpoint signaling. Primary fibroblasts also upregulate Claspin and Timeless in response to oncogene-induced replication stress independently of ATR signaling, indicating a fork-protective gain-of-function role beyond checkpoint activation.","method":"DNA fiber assay, siRNA knockdown, checkpoint signaling western blots, primary tumor sample expression analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — direct fork protection measured by DNA fiber assay combined with checkpoint assays and orthogonal cell models; strong evidence for checkpoint-independent role","pmids":["30796221"],"is_preprint":false},{"year":2025,"finding":"ALKBH5-mediated m6A demethylation reduces CLSPN mRNA stability in an IGF2BP2-dependent manner. When ALKBH5 is low (as in CRPC), IGF2BP2 reads m6A marks on CLSPN mRNA to stabilize it, increasing Claspin protein levels and promoting docetaxel resistance in prostate cancer. Knocking down IGF2BP2 reverses this resistance, establishing the ALKBH5-IGF2BP2 axis as an epitranscriptomic regulator of CLSPN expression and drug resistance.","method":"m6A sequencing, RNA stability assay, Co-IP, siRNA knockdown, organoid models, clinical sample validation","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — multi-omics and functional knockdown with organoid validation; single lab but orthogonal methods","pmids":["41069850"],"is_preprint":false}],"current_model":"Claspin is a nuclear adaptor/mediator protein that, upon ATR-dependent phosphorylation during replication stress or DNA damage, selectively bridges ATR (and the 9-1-1 complex) to Chk1 to activate the replication checkpoint; it works downstream of TopBP1 and cooperates with BRCA1, while also protecting replication forks in a checkpoint-independent manner; its levels are tightly regulated through Plk1-mediated phosphorylation of a DSGxxS degron enabling SCF-βTrCP-dependent ubiquitylation and proteasomal degradation at mitotic entry—a process counteracted by USP28 deubiquitylation and APC/C(Cdh1) pathway modulation during G2 damage responses—and at the RNA level by the ALKBH5-IGF2BP2 m6A axis."},"narrative":{"teleology":[{"year":2000,"claim":"The identification of Claspin as a Chk1-binding protein whose immunodepletion abolished Chk1 activation in Xenopus egg extracts established it as the first dedicated mediator of the replication checkpoint, answering how the ATR signal is transmitted specifically to Chk1.","evidence":"Co-immunoprecipitation and immunodepletion in Xenopus egg extracts with kinase activity assays","pmids":["11090622"],"confidence":"High","gaps":["Mechanism of Claspin–Chk1 interaction remained undefined","Human ortholog function not yet confirmed","Whether Claspin acted on other checkpoint effectors was unknown"]},{"year":2003,"claim":"Extension to human cells revealed that Claspin is a cell-cycle-regulated nuclear protein that associates with Chk1 only after replication stress, and interacts with ATR and Rad9, establishing it as a damage-induced adaptor bridging the sensor and effector kinases.","evidence":"Co-immunoprecipitation, siRNA knockdown, and checkpoint assays in human cells","pmids":["12766152"],"confidence":"High","gaps":["Structural basis for phosphorylation-dependent Chk1 binding unknown","Relationship to other mediators such as TopBP1 undefined"]},{"year":2004,"claim":"Discovery that ATR-dependent phosphorylation of Claspin induces a Claspin–BRCA1 complex controlling BRCA1 Ser1524 phosphorylation expanded the model from a linear ATR→Claspin→Chk1 relay to a branched signaling network coordinating BRCA1 and Chk1 activation.","evidence":"Reciprocal co-immunoprecipitation, phosphorylation mapping, and cell proliferation assays","pmids":["15096610"],"confidence":"High","gaps":["Whether the Claspin–BRCA1 interaction is direct or scaffold-mediated was not resolved","Functional significance of BRCA1 Ser1524 phosphorylation downstream unclear"]},{"year":2006,"claim":"Epistasis experiments placed Claspin downstream of TopBP1 and showed it selectively mediates Chk1 phosphorylation without affecting other ATR substrates, resolving the pathway hierarchy and demonstrating substrate specificity in checkpoint signaling.","evidence":"RNAi-based epistasis, systematic ATR substrate phosphorylation analysis, immunofluorescence","pmids":["16880517"],"confidence":"High","gaps":["How TopBP1 enables the Claspin–Chk1 interaction mechanistically was not defined","Whether Claspin has checkpoint-independent roles was unknown"]},{"year":2006,"claim":"Three concurrent studies demonstrated that Plk1 phosphorylates a DSGxxS degron in Claspin, enabling SCF-βTrCP-mediated ubiquitylation and proteasomal degradation at mitotic entry; non-degradable Claspin mutants prolonged Chk1 activation and delayed mitosis, answering how checkpoint signaling is terminated during recovery.","evidence":"In vitro ubiquitylation, degron mutagenesis, co-immunoprecipitation, flow cytometry, and live-cell imaging across three independent laboratories","pmids":["16885022","16885021","16934469"],"confidence":"High","gaps":["Additional post-translational modifications controlling Claspin turnover beyond the degron were not mapped","Whether Claspin degradation contributes to unperturbed cell-cycle progression was unclear"]},{"year":2006,"claim":"Identification of USP28 as a deubiquitylase that stabilizes Claspin during DNA damage revealed a counteracting mechanism to SCF-βTrCP-driven degradation, explaining how Claspin levels are maintained to sustain checkpoint signaling.","evidence":"53BP1 complex purification, siRNA knockdown, Claspin protein level measurement","pmids":["16901786"],"confidence":"Medium","gaps":["Direct deubiquitylation of Claspin by USP28 was not reconstituted in vitro","Specificity of USP28 for Claspin versus other checkpoint mediators not resolved"]},{"year":2006,"claim":"The Tim–Tipin complex was shown to be required for Claspin nuclear accumulation under replication stress, identifying an upstream regulatory step that ensures proper Claspin localization for checkpoint activation.","evidence":"siRNA knockdown, subcellular fractionation, immunofluorescence","pmids":["17102137"],"confidence":"Medium","gaps":["Mechanism by which Tim–Tipin promotes Claspin nuclear retention unknown","Whether Tim–Tipin directly binds Claspin was not demonstrated"]},{"year":2008,"claim":"Discovery that APC/C(Cdh1)—activated via Cdc14B-mediated Plk1 degradation—stabilizes Claspin in G2 damage responses by removing the Plk1-driven degradation signal integrated the Claspin turnover circuit into the broader cell-cycle E3 ligase network, explaining how Claspin is protected during G2 checkpoint activation.","evidence":"In vivo ubiquitylation assays, siRNA epistasis, substrate degradation assays, cell-cycle synchronization","pmids":["18662541"],"confidence":"High","gaps":["Whether Claspin is a direct APC/C(Cdh1) substrate (via a D-box or KEN-box) was not fully mapped","Relative contributions of USP28 versus APC/C(Cdh1)-Plk1 axis to Claspin stabilization were not quantified"]},{"year":2019,"claim":"Demonstration that Claspin protects replication forks from oncogene-induced stress independently of ATR–Chk1 checkpoint signaling revealed a second, mechanistically distinct function—fork stabilization—explaining why Claspin and Timeless are upregulated in tumors beyond their checkpoint roles.","evidence":"DNA fiber assays, siRNA titration to pretumoral levels, checkpoint signaling western blots, primary tumor expression analysis","pmids":["30796221"],"confidence":"High","gaps":["Molecular mechanism by which Claspin stabilizes forks independently of Chk1 was not identified","Whether fork protection requires Claspin's known interaction domains is unknown"]},{"year":2020,"claim":"Functional analysis of CLSPN coding and promoter variants linked to breast cancer showed that a missense/splicing variant reduces Claspin expression and Chk1 activation, connecting CLSPN genetic variation to checkpoint competence and cancer susceptibility.","evidence":"Minigene splicing assay, luciferase reporter, western blotting for Chk1 phosphorylation, association study","pmids":["32847043"],"confidence":"Medium","gaps":["Association-level evidence; not yet validated by family-based segregation or CRISPR knock-in","Effect size of individual variants on cancer risk not precisely determined"]},{"year":2025,"claim":"Identification of the ALKBH5–IGF2BP2 m6A axis as an epitranscriptomic regulator of CLSPN mRNA stability added a new layer of post-transcriptional control, explaining elevated Claspin expression and docetaxel resistance in castration-resistant prostate cancer.","evidence":"m6A-seq, RNA stability assays, siRNA knockdown of IGF2BP2, organoid models, clinical sample validation","pmids":["41069850"],"confidence":"Medium","gaps":["m6A sites on CLSPN mRNA were not individually mutated to confirm causality","Whether this regulatory axis operates in non-prostate cancer contexts is unknown"]},{"year":null,"claim":"The molecular mechanism by which Claspin stabilizes replication forks independently of Chk1 remains undefined, as does the structural basis for its selective bridging of ATR to Chk1; whether disease-associated CLSPN variants confer clinically actionable cancer risk is also unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of Claspin in complex with Chk1 or replication fork substrates","Checkpoint-independent fork protection mechanism uncharacterized","Clinical significance of CLSPN variants not established by prospective studies"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,3]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3,8]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[1,2,3]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[0,11]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4,5,6,9]}],"complexes":["SCF-βTrCP (substrate)","APC/C(Cdh1) (substrate)"],"partners":["CHEK1","ATR","RAD9A","BRCA1","TOPBP1","PLK1","BTRC","TIMELESS"],"other_free_text":[]},"mechanistic_narrative":"Claspin is a nuclear adaptor protein essential for activating the ATR–Chk1 replication checkpoint in response to DNA replication stress and genotoxic damage. It binds Chk1 in a phosphorylation-dependent manner downstream of TopBP1 and ATR, selectively mediating Chk1 phosphorylation without affecting other ATR substrates, and also recruits BRCA1 to coordinate checkpoint signaling [PMID:11090622, PMID:12766152, PMID:16880517, PMID:15096610]. Beyond checkpoint mediation, Claspin protects replication forks from oncogene-induced stress in a checkpoint-independent manner, a function upregulated in cancer cells [PMID:30796221]. Claspin protein levels are tightly controlled through Plk1-dependent phosphorylation of a DSGxxS degron that triggers SCF-βTrCP ubiquitylation and proteasomal degradation at mitotic entry—a process counteracted during DNA damage by USP28 deubiquitylation and APC/C(Cdh1)-mediated Plk1 downregulation—and at the mRNA level by an ALKBH5–IGF2BP2 m6A regulatory axis [PMID:16885022, PMID:18662541, PMID:41069850]."},"prefetch_data":{"uniprot":{"accession":"Q9HAW4","full_name":"Claspin","aliases":[],"length_aa":1339,"mass_kda":151.1,"function":"Required for checkpoint mediated cell cycle arrest in response to inhibition of DNA replication or to DNA damage induced by both ionizing and UV irradiation (PubMed:12766152, PubMed:15190204, PubMed:15707391, PubMed:16123041). Adapter protein which binds to BRCA1 and the checkpoint kinase CHEK1 and facilitates the ATR-dependent phosphorylation of both proteins (PubMed:12766152, PubMed:15096610, PubMed:15707391, PubMed:16123041). Also required to maintain normal rates of replication fork progression during unperturbed DNA replication. Binds directly to DNA, with particular affinity for branched or forked molecules and interacts with multiple protein components of the replisome such as the MCM2-7 complex and TIMELESS (PubMed:15226314, PubMed:34694004, PubMed:35585232). Important for initiation of DNA replication, recruits kinase CDC7 to phosphorylate MCM2-7 components (PubMed:27401717)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9HAW4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CLSPN","classification":"Common Essential","n_dependent_lines":1004,"n_total_lines":1208,"dependency_fraction":0.8311258278145696},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CSNK2B","stoichiometry":0.2},{"gene":"MIF","stoichiometry":0.2},{"gene":"SRP14","stoichiometry":0.2},{"gene":"SRP9","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/CLSPN","total_profiled":1310},"omim":[{"mim_id":"620302","title":"WD REPEAT-CONTAINING PROTEIN 76; WDR76","url":"https://www.omim.org/entry/620302"},{"mim_id":"610716","title":"TIMELESS-INTERACTING PROTEIN; TIPIN","url":"https://www.omim.org/entry/610716"},{"mim_id":"605434","title":"CLASPIN; CLSPN","url":"https://www.omim.org/entry/605434"},{"mim_id":"603887","title":"TIMELESS CIRCADIAN REGULATOR; TIMELESS","url":"https://www.omim.org/entry/603887"},{"mim_id":"603482","title":"BETA-TRANSDUCIN REPEAT-CONTAINING PROTEIN; BTRC","url":"https://www.omim.org/entry/603482"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Golgi apparatus","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":10.6},{"tissue":"lymphoid tissue","ntpm":7.3},{"tissue":"retina","ntpm":6.3},{"tissue":"testis","ntpm":5.4}],"url":"https://www.proteinatlas.org/search/CLSPN"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9HAW4","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HAW4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HAW4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HAW4-F1-predicted_aligned_error_v6.png","plddt_mean":50.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CLSPN","jax_strain_url":"https://www.jax.org/strain/search?query=CLSPN"},"sequence":{"accession":"Q9HAW4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HAW4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HAW4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HAW4"}},"corpus_meta":[{"pmid":"18077083","id":"PMC_18077083","title":"Germline alterations in the CLSPN gene in breast cancer families.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18077083","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38237848","id":"PMC_38237848","title":"CLSPN actives Wnt/β-catenin signaling to facilitate glycolysis and cell proliferation in oral squamous cell carcinoma.","date":"2024","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38237848","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34269180","id":"PMC_34269180","title":"circRNA derived from CLSPN (circCLSPN) is an oncogene in human glioblastoma multiforme by regulating cell growth, migration and invasion via ceRNA pathway.","date":"2021","source":"Journal of biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34269180","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32847043","id":"PMC_32847043","title":"Implications of CLSPN Variants in Cellular Function and Susceptibility to Cancer.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32847043","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38256171","id":"PMC_38256171","title":"The Interaction between CLSPN Gene Polymorphisms and Alcohol Consumption Contributes to Oral Cancer Progression.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38256171","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41069850","id":"PMC_41069850","title":"ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41069850","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40275302","id":"PMC_40275302","title":"Potential of CLSPN as a therapeutic target in melanoma: a key player in melanoma progression and tumor microenvironment.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40275302","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41656416","id":"PMC_41656416","title":"Integrating multi-omics analysis identifies DNA damage-related gene CLSPN as a biomarker in gastric cancer.","date":"2026","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41656416","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39539024","id":"PMC_39539024","title":"Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization.","date":"2024","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39539024","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12791985","id":"PMC_12791985","title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12791985","citation_count":2197,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29395067","id":"PMC_29395067","title":"High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29395067","citation_count":580,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11090622","id":"PMC_11090622","title":"Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts.","date":"2000","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11090622","citation_count":355,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18662541","id":"PMC_18662541","title":"The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18662541","citation_count":334,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16901786","id":"PMC_16901786","title":"A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16901786","citation_count":291,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16885022","id":"PMC_16885022","title":"SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16885022","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30033366","id":"PMC_30033366","title":"Mapping the Genetic Landscape of Human Cells.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/30033366","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22017875","id":"PMC_22017875","title":"mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22017875","citation_count":216,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16885021","id":"PMC_16885021","title":"Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16885021","citation_count":215,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12766152","id":"PMC_12766152","title":"Human claspin is required for replication checkpoint control.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12766152","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26673895","id":"PMC_26673895","title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26673895","citation_count":198,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16934469","id":"PMC_16934469","title":"Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery.","date":"2006","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/16934469","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30686591","id":"PMC_30686591","title":"Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30686591","citation_count":167,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24126761","id":"PMC_24126761","title":"hPrimpol1/CCDC111 is a human DNA primase-polymerase required for the maintenance of genome integrity.","date":"2013","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/24126761","citation_count":160,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30415952","id":"PMC_30415952","title":"MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30415952","citation_count":152,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16710414","id":"PMC_16710414","title":"The DNA sequence and biological annotation of human chromosome 1.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16710414","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16880517","id":"PMC_16880517","title":"Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16880517","citation_count":141,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15096610","id":"PMC_15096610","title":"Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15096610","citation_count":125,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17102137","id":"PMC_17102137","title":"Human Tim/Timeless-interacting protein, Tipin, is required for efficient progression of S phase and DNA replication checkpoint.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17102137","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30796221","id":"PMC_30796221","title":"Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30796221","citation_count":110,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6059,"output_tokens":849,"usd":0.015456},"stage2":{"model":"claude-opus-4-6","input_tokens":4060,"output_tokens":1258,"usd":0.077625},"total_usd":0.310796,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":17703,"output_tokens":3619,"usd":0.053697},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7259,"output_tokens":2922,"usd":0.164018}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"A CLSPN variant (c.1574A>G, p.Asn525Ser) causes partial exon skipping and decreased Claspin expression, resulting in reduced CHK1 activation, as demonstrated by minigene splicing assay and signaling experiments.\",\n      \"method\": \"Minigene splicing assay, western blotting for CHK1 activation\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal methods (splicing assay + signaling), single lab\",\n      \"pmids\": [\"32847043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A CLSPN promoter variant (c.-68C>T) increases CLSPN transcriptional activity, as shown by luciferase reporter assay.\",\n      \"method\": \"Luciferase reporter assay\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single method, single lab\",\n      \"pmids\": [\"32847043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CLSPN promotes glycolysis and cell proliferation in oral squamous cell carcinoma through activation of the Wnt/β-catenin signaling pathway; knockdown of Wnt3a reversed the pro-glycolytic and pro-proliferative effects of CLSPN overexpression.\",\n      \"method\": \"Overexpression/knockdown with ECAR, glucose uptake, lactate production assays, western blotting for Wnt3a and β-catenin, rescue experiments, in vivo xenograft\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — multiple functional assays with rescue experiment, single lab\",\n      \"pmids\": [\"38237848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ALKBH5-mediated m6A demethylation reduces CLSPN mRNA stability in an IGF2BP2-dependent manner; loss of ALKBH5 stabilizes CLSPN mRNA via the m6A reader IGF2BP2, promoting docetaxel resistance in prostate cancer.\",\n      \"method\": \"Multi-omics analysis, overexpression/knockdown of ALKBH5 and IGF2BP2, mRNA stability assays, organoid models, clinical sample validation\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic epistasis with multi-omics and functional rescue, single lab\",\n      \"pmids\": [\"41069850\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Claspin (CLSPN) functions as a DNA replication stress regulator that activates CHK1 (with certain variants reducing this activation), and whose mRNA stability is post-transcriptionally regulated by m6A modification via the ALKBH5-IGF2BP2 axis; it also promotes glycolysis and cell proliferation through Wnt/β-catenin signaling in some cancer contexts.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Claspin (identified in Xenopus egg extracts) is a novel protein that binds to Chk1; this binding is elevated in the presence of checkpoint-activating DNA templates. Immunodepletion of Claspin abolishes both phosphorylation and activation of Chk1 and prevents cell-cycle arrest in response to DNA replication blocks, establishing Claspin as an essential upstream regulator of Chk1.\",\n      \"method\": \"Protein identification, co-immunoprecipitation, immunodepletion from Xenopus egg extracts, kinase activity assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution in egg extracts with immunodepletion and direct kinase activation assay; foundational paper replicated by multiple subsequent studies\",\n      \"pmids\": [\"11090622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Human Claspin is a cell-cycle regulated protein peaking at S/G2 phase that localizes to the nucleus and associates with Chk1 only following replication stress or DNA damage. Claspin is phosphorylated in response to replication stress, and this phosphorylation is required for its association with Chk1. Claspin also interacts with ATR and Rad9 (of the 9-1-1 complex), suggesting it acts as an adaptor bringing these checkpoint components together. siRNA-mediated knockdown of Claspin inhibits Chk1 activation and impairs the replication checkpoint.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, cell-cycle analysis, premature chromatin condensation assay, DNA synthesis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, siRNA, checkpoint readouts) in human cells; independently consistent with Xenopus findings\",\n      \"pmids\": [\"12766152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Human Claspin is required for resistance to multiple genotoxic stresses (UV, IR, hydroxyurea). ATR-dependent phosphorylation of Claspin induces formation of a Claspin-BRCA1 complex. Claspin controls BRCA1 phosphorylation on serine 1524, suggesting a model where ATR phosphorylates Claspin, which recruits BRCA1 to jointly activate Chk1. Additionally, Claspin overexpression promotes cell proliferation, indicating a dual role as both a checkpoint mediator and a positive cell-cycle regulator.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, phosphorylation mapping, cell proliferation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, reciprocal Co-IP, and defined phosphorylation site with functional readouts\",\n      \"pmids\": [\"15096610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Claspin operates downstream of TopBP1 in the ATR signaling pathway and selectively mediates ATR-dependent phosphorylation of Chk1, but not other ATR substrates (Nbs1, Smc1, H2AX). Unlike TopBP1, Claspin remains distributed throughout the nucleus after DNA damage. TopBP1 is required for the DNA damage-induced interaction between Claspin and Chk1. Claspin depletion mimics Chk1 inactivation by inducing spontaneous DNA damage.\",\n      \"method\": \"RNAi knockdown, immunofluorescence, co-immunoprecipitation, western blotting for ATR substrate phosphorylation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis defined by orthogonal RNAi experiments; substrate specificity established by systematic phosphorylation analysis\",\n      \"pmids\": [\"16880517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"During recovery from the DNA replication checkpoint, Claspin is degraded via the SCF-βTrCP ubiquitin ligase. Plk1 phosphorylates a canonical DSGxxS degron in Claspin, enabling βTrCP binding and ubiquitylation. A stable Claspin mutant unable to bind βTrCP prolongs Chk1 activation and delays mitotic entry. In G2 DNA damage responses, Claspin proteolysis is inhibited to allow checkpoint maintenance.\",\n      \"method\": \"In vitro ubiquitylation assay, degron mutagenesis, co-immunoprecipitation, stable mutant expression, flow cytometry\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro ubiquitylation reconstitution with mutagenesis of degron, corroborated by functional cell-cycle assays; replicated in parallel by two independent labs\",\n      \"pmids\": [\"16885022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Claspin is degraded at the onset of mitosis via its interaction with SCF-βTrCP; this interaction is phosphorylation-dependent, requires Plk1 activity, and depends on an intact phosphodegron in the N-terminus of Claspin. Stabilized Claspin (phosphodegron mutant or βTrCP knockdown) impairs Chk1 dephosphorylation and delays G2/M transition during recovery from checkpoint arrest. Thus, Plk1-driven Claspin degradation is essential for timely checkpoint recovery.\",\n      \"method\": \"Ubiquitylation assay, phosphodegron mutagenesis, siRNA, co-immunoprecipitation, live-cell imaging, flow cytometry\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods; independent replication alongside Peschiaroli et al. 2006 in the same journal issue\",\n      \"pmids\": [\"16885021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Plk1-dependent proteasomal degradation of Claspin at mitotic entry controls termination of the Chk1-mediated checkpoint. Claspin interacts directly with both βTrCP and Plk1; inactivation of either or mutation of the βTrCP recognition motif in Claspin prevents mitotic degradation. A non-degradable Claspin mutant inhibits recovery from DNA-damage checkpoint arrest. Chk1 activity stabilizes Claspin during checkpoint response.\",\n      \"method\": \"Co-immunoprecipitation, proteasome inhibition, dominant-negative and RNAi approaches, flow cytometry, mitotic progression assay\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Plk1-Claspin and βTrCP-Claspin interaction shown with mutagenesis; functional checkpoint-recovery readout; consistent with two concurrent papers\",\n      \"pmids\": [\"16934469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The deubiquitylating enzyme USP28 is required to stabilize Claspin (and other checkpoint mediators including Mdc1 and TopBP1) in response to DNA damage, counteracting ubiquitin-mediated degradation and sustaining checkpoint signaling.\",\n      \"method\": \"Co-immunoprecipitation via 53BP1 complex purification, siRNA knockdown, western blotting for Claspin stability\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Claspin stabilization by USP28 demonstrated by knockdown and protein level measurement; single lab, but consistent mechanistic logic\",\n      \"pmids\": [\"16901786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Tim (Timeless) and its interacting partner Tipin facilitate the accumulation of Claspin in the nucleus under replication stress conditions. Knockdown of Tipin or Tim causes mislocalization of Claspin to the cytoplasm and impairs Chk1 phosphorylation under replication stress, demonstrating that the Tim-Tipin complex regulates Claspin nuclear localization and is required for full checkpoint signaling.\",\n      \"method\": \"siRNA knockdown, subcellular fractionation, immunofluorescence, Chk1 phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional consequence (Chk1 activation); single lab\",\n      \"pmids\": [\"17102137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In response to genotoxic stress in G2, APC/C(Cdh1) activation (triggered by Cdc14B-mediated Plk1 degradation) stabilizes Claspin by reducing Plk1-dependent phosphorylation required for βTrCP-mediated degradation. Claspin is also identified as an APC/C(Cdh1) substrate in G1. The deubiquitylating enzyme Usp28 counteracts APC/C(Cdh1)-mediated Claspin ubiquitylation to permit Claspin-mediated Chk1 activation in G2 damage response.\",\n      \"method\": \"In vivo ubiquitylation assay, co-immunoprecipitation, siRNA, substrate degradation assay, cell-cycle synchronization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal mechanistic methods (ubiquitylation, Co-IP, degradation assays, epistasis); defines a novel APC/C(Cdh1) regulatory circuit for Claspin\",\n      \"pmids\": [\"18662541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The CLSPN variant c.1574A>G (p.Asn525Ser) causes partial exon skipping and decreased Claspin expression, and reduces Chk1 activation in signaling experiments. This variant is significantly associated with breast cancer. A promoter variant c.-68C>T increases CLSPN transcriptional activity in a luciferase assay. These results demonstrate that CLSPN variants can modulate Claspin function by altering transcription, RNA processing, and Chk1 activation.\",\n      \"method\": \"Minigene splicing assay, luciferase reporter assay, western blotting for Chk1 activation, association study\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional splicing and signaling assays with defined variants; single lab\",\n      \"pmids\": [\"32847043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Claspin (and Timeless) are overexpressed in cancer cells and function to protect replication forks from oncogene-induced replication stress in a checkpoint-independent manner. Reducing Claspin and Timeless to pretumoral levels impedes fork progression without affecting ATR-Chk1 checkpoint signaling. Primary fibroblasts also upregulate Claspin and Timeless in response to oncogene-induced replication stress independently of ATR signaling, indicating a fork-protective gain-of-function role beyond checkpoint activation.\",\n      \"method\": \"DNA fiber assay, siRNA knockdown, checkpoint signaling western blots, primary tumor sample expression analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct fork protection measured by DNA fiber assay combined with checkpoint assays and orthogonal cell models; strong evidence for checkpoint-independent role\",\n      \"pmids\": [\"30796221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ALKBH5-mediated m6A demethylation reduces CLSPN mRNA stability in an IGF2BP2-dependent manner. When ALKBH5 is low (as in CRPC), IGF2BP2 reads m6A marks on CLSPN mRNA to stabilize it, increasing Claspin protein levels and promoting docetaxel resistance in prostate cancer. Knocking down IGF2BP2 reverses this resistance, establishing the ALKBH5-IGF2BP2 axis as an epitranscriptomic regulator of CLSPN expression and drug resistance.\",\n      \"method\": \"m6A sequencing, RNA stability assay, Co-IP, siRNA knockdown, organoid models, clinical sample validation\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-omics and functional knockdown with organoid validation; single lab but orthogonal methods\",\n      \"pmids\": [\"41069850\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Claspin is a nuclear adaptor/mediator protein that, upon ATR-dependent phosphorylation during replication stress or DNA damage, selectively bridges ATR (and the 9-1-1 complex) to Chk1 to activate the replication checkpoint; it works downstream of TopBP1 and cooperates with BRCA1, while also protecting replication forks in a checkpoint-independent manner; its levels are tightly regulated through Plk1-mediated phosphorylation of a DSGxxS degron enabling SCF-βTrCP-dependent ubiquitylation and proteasomal degradation at mitotic entry—a process counteracted by USP28 deubiquitylation and APC/C(Cdh1) pathway modulation during G2 damage responses—and at the RNA level by the ALKBH5-IGF2BP2 m6A axis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CLSPN (Claspin) functions as a mediator in the DNA replication stress checkpoint by promoting CHK1 activation; a coding variant (p.Asn525Ser) that causes partial exon skipping reduces Claspin expression and impairs CHK1 phosphorylation [PMID:32847043]. CLSPN mRNA stability is regulated by m6A modification: ALKBH5-mediated demethylation destabilizes the transcript, while loss of ALKBH5 allows IGF2BP2-dependent stabilization of CLSPN mRNA, contributing to docetaxel resistance in prostate cancer [PMID:41069850]. In oral squamous cell carcinoma, CLSPN promotes glycolysis and cell proliferation through activation of the Wnt/β-catenin signaling pathway, as demonstrated by rescue experiments with Wnt3a knockdown [PMID:38237848].\",\n  \"teleology\": [\n    {\n      \"year\": 2020,\n      \"claim\": \"A coding variant and a promoter variant established that CLSPN expression level directly controls CHK1 checkpoint activation, linking Claspin abundance to replication stress signaling output.\",\n      \"evidence\": \"Minigene splicing assay showing exon skipping from c.1574A>G (p.Asn525Ser) and luciferase reporter assay for c.-68C>T promoter variant, with western blotting for CHK1 phosphorylation\",\n      \"pmids\": [\"32847043\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Effects demonstrated only in reporter/minigene systems without endogenous knock-in validation\",\n        \"Downstream consequences of reduced CHK1 activation on DNA damage response not characterized\",\n        \"No structural basis for how Asn525Ser disrupts splicing\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Beyond checkpoint signaling, CLSPN was shown to drive glycolysis and proliferation through Wnt/β-catenin activation, revealing a checkpoint-independent oncogenic role.\",\n      \"evidence\": \"Overexpression and knockdown in oral squamous cell carcinoma cells with ECAR, glucose uptake, lactate production assays, western blotting, Wnt3a rescue experiments, and in vivo xenograft\",\n      \"pmids\": [\"38237848\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which CLSPN activates Wnt/β-catenin signaling is not defined\",\n        \"Whether this metabolic function is separable from CLSPN's checkpoint role is unknown\",\n        \"Findings limited to a single cancer type without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The discovery that ALKBH5-mediated m6A demethylation destabilizes CLSPN mRNA via IGF2BP2 established an epitranscriptomic layer of CLSPN regulation and linked it to chemoresistance.\",\n      \"evidence\": \"Multi-omics analysis, ALKBH5/IGF2BP2 overexpression and knockdown, mRNA stability assays, organoid models, and clinical sample validation in prostate cancer\",\n      \"pmids\": [\"41069850\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific m6A sites on CLSPN mRNA responsible for IGF2BP2 binding not mapped at nucleotide resolution\",\n        \"Whether m6A-mediated CLSPN regulation affects CHK1 checkpoint signaling or operates through the Wnt axis is unresolved\",\n        \"Findings from a single lab without independent validation\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CLSPN's canonical checkpoint-mediator function and its emerging roles in metabolic reprogramming and Wnt signaling are coordinated remains unknown, as does whether these represent the same or distinct protein pools.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model of full-length human Claspin exists\",\n        \"Direct physical interaction between CLSPN and Wnt pathway components has not been demonstrated\",\n        \"Whether CLSPN's metabolic and checkpoint roles are separable by domain has not been tested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CHEK1\",\n      \"ALKBH5\",\n      \"IGF2BP2\",\n      \"WNT3A\",\n      \"CTNNB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Claspin is a nuclear adaptor protein essential for activating the ATR–Chk1 replication checkpoint in response to DNA replication stress and genotoxic damage. It binds Chk1 in a phosphorylation-dependent manner downstream of TopBP1 and ATR, selectively mediating Chk1 phosphorylation without affecting other ATR substrates, and also recruits BRCA1 to coordinate checkpoint signaling [PMID:11090622, PMID:12766152, PMID:16880517, PMID:15096610]. Beyond checkpoint mediation, Claspin protects replication forks from oncogene-induced stress in a checkpoint-independent manner, a function upregulated in cancer cells [PMID:30796221]. Claspin protein levels are tightly controlled through Plk1-dependent phosphorylation of a DSGxxS degron that triggers SCF-βTrCP ubiquitylation and proteasomal degradation at mitotic entry—a process counteracted during DNA damage by USP28 deubiquitylation and APC/C(Cdh1)-mediated Plk1 downregulation—and at the mRNA level by an ALKBH5–IGF2BP2 m6A regulatory axis [PMID:16885022, PMID:18662541, PMID:41069850].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"The identification of Claspin as a Chk1-binding protein whose immunodepletion abolished Chk1 activation in Xenopus egg extracts established it as the first dedicated mediator of the replication checkpoint, answering how the ATR signal is transmitted specifically to Chk1.\",\n      \"evidence\": \"Co-immunoprecipitation and immunodepletion in Xenopus egg extracts with kinase activity assays\",\n      \"pmids\": [\"11090622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Claspin–Chk1 interaction remained undefined\", \"Human ortholog function not yet confirmed\", \"Whether Claspin acted on other checkpoint effectors was unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Extension to human cells revealed that Claspin is a cell-cycle-regulated nuclear protein that associates with Chk1 only after replication stress, and interacts with ATR and Rad9, establishing it as a damage-induced adaptor bridging the sensor and effector kinases.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, and checkpoint assays in human cells\",\n      \"pmids\": [\"12766152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for phosphorylation-dependent Chk1 binding unknown\", \"Relationship to other mediators such as TopBP1 undefined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery that ATR-dependent phosphorylation of Claspin induces a Claspin–BRCA1 complex controlling BRCA1 Ser1524 phosphorylation expanded the model from a linear ATR→Claspin→Chk1 relay to a branched signaling network coordinating BRCA1 and Chk1 activation.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation, phosphorylation mapping, and cell proliferation assays\",\n      \"pmids\": [\"15096610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the Claspin–BRCA1 interaction is direct or scaffold-mediated was not resolved\", \"Functional significance of BRCA1 Ser1524 phosphorylation downstream unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Epistasis experiments placed Claspin downstream of TopBP1 and showed it selectively mediates Chk1 phosphorylation without affecting other ATR substrates, resolving the pathway hierarchy and demonstrating substrate specificity in checkpoint signaling.\",\n      \"evidence\": \"RNAi-based epistasis, systematic ATR substrate phosphorylation analysis, immunofluorescence\",\n      \"pmids\": [\"16880517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TopBP1 enables the Claspin–Chk1 interaction mechanistically was not defined\", \"Whether Claspin has checkpoint-independent roles was unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Three concurrent studies demonstrated that Plk1 phosphorylates a DSGxxS degron in Claspin, enabling SCF-βTrCP-mediated ubiquitylation and proteasomal degradation at mitotic entry; non-degradable Claspin mutants prolonged Chk1 activation and delayed mitosis, answering how checkpoint signaling is terminated during recovery.\",\n      \"evidence\": \"In vitro ubiquitylation, degron mutagenesis, co-immunoprecipitation, flow cytometry, and live-cell imaging across three independent laboratories\",\n      \"pmids\": [\"16885022\", \"16885021\", \"16934469\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Additional post-translational modifications controlling Claspin turnover beyond the degron were not mapped\", \"Whether Claspin degradation contributes to unperturbed cell-cycle progression was unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of USP28 as a deubiquitylase that stabilizes Claspin during DNA damage revealed a counteracting mechanism to SCF-βTrCP-driven degradation, explaining how Claspin levels are maintained to sustain checkpoint signaling.\",\n      \"evidence\": \"53BP1 complex purification, siRNA knockdown, Claspin protein level measurement\",\n      \"pmids\": [\"16901786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct deubiquitylation of Claspin by USP28 was not reconstituted in vitro\", \"Specificity of USP28 for Claspin versus other checkpoint mediators not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The Tim–Tipin complex was shown to be required for Claspin nuclear accumulation under replication stress, identifying an upstream regulatory step that ensures proper Claspin localization for checkpoint activation.\",\n      \"evidence\": \"siRNA knockdown, subcellular fractionation, immunofluorescence\",\n      \"pmids\": [\"17102137\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which Tim–Tipin promotes Claspin nuclear retention unknown\", \"Whether Tim–Tipin directly binds Claspin was not demonstrated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that APC/C(Cdh1)—activated via Cdc14B-mediated Plk1 degradation—stabilizes Claspin in G2 damage responses by removing the Plk1-driven degradation signal integrated the Claspin turnover circuit into the broader cell-cycle E3 ligase network, explaining how Claspin is protected during G2 checkpoint activation.\",\n      \"evidence\": \"In vivo ubiquitylation assays, siRNA epistasis, substrate degradation assays, cell-cycle synchronization\",\n      \"pmids\": [\"18662541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Claspin is a direct APC/C(Cdh1) substrate (via a D-box or KEN-box) was not fully mapped\", \"Relative contributions of USP28 versus APC/C(Cdh1)-Plk1 axis to Claspin stabilization were not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstration that Claspin protects replication forks from oncogene-induced stress independently of ATR–Chk1 checkpoint signaling revealed a second, mechanistically distinct function—fork stabilization—explaining why Claspin and Timeless are upregulated in tumors beyond their checkpoint roles.\",\n      \"evidence\": \"DNA fiber assays, siRNA titration to pretumoral levels, checkpoint signaling western blots, primary tumor expression analysis\",\n      \"pmids\": [\"30796221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which Claspin stabilizes forks independently of Chk1 was not identified\", \"Whether fork protection requires Claspin's known interaction domains is unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Functional analysis of CLSPN coding and promoter variants linked to breast cancer showed that a missense/splicing variant reduces Claspin expression and Chk1 activation, connecting CLSPN genetic variation to checkpoint competence and cancer susceptibility.\",\n      \"evidence\": \"Minigene splicing assay, luciferase reporter, western blotting for Chk1 phosphorylation, association study\",\n      \"pmids\": [\"32847043\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Association-level evidence; not yet validated by family-based segregation or CRISPR knock-in\", \"Effect size of individual variants on cancer risk not precisely determined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of the ALKBH5–IGF2BP2 m6A axis as an epitranscriptomic regulator of CLSPN mRNA stability added a new layer of post-transcriptional control, explaining elevated Claspin expression and docetaxel resistance in castration-resistant prostate cancer.\",\n      \"evidence\": \"m6A-seq, RNA stability assays, siRNA knockdown of IGF2BP2, organoid models, clinical sample validation\",\n      \"pmids\": [\"41069850\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"m6A sites on CLSPN mRNA were not individually mutated to confirm causality\", \"Whether this regulatory axis operates in non-prostate cancer contexts is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular mechanism by which Claspin stabilizes replication forks independently of Chk1 remains undefined, as does the structural basis for its selective bridging of ATR to Chk1; whether disease-associated CLSPN variants confer clinically actionable cancer risk is also unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of Claspin in complex with Chk1 or replication fork substrates\", \"Checkpoint-independent fork protection mechanism uncharacterized\", \"Clinical significance of CLSPN variants not established by prospective studies\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [1, 2, 3]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 5, 6, 9]}\n    ],\n    \"complexes\": [\n      \"SCF-βTrCP (substrate)\",\n      \"APC/C(Cdh1) (substrate)\"\n    ],\n    \"partners\": [\n      \"CHEK1\",\n      \"ATR\",\n      \"RAD9A\",\n      \"BRCA1\",\n      \"TOPBP1\",\n      \"PLK1\",\n      \"BTRC\",\n      \"TIMELESS\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}